Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 628Neoplasm Metastasis 38HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Inflammatory Breast Neoplasms 20Brain Neoplasms 18Stomach Neoplasms 16Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Triple Negative Breast Neoplasms 12Colorectal Neoplasms 10Pancreatic Neoplasms 9Endometrial Neoplasms 9Ovarian Neoplasms 8Cardiotoxicity 8Lung Neoplasms 7Esophageal Neoplasms 7Breast Diseases 7Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pathologic Complete Response 5Carcinoma, Ductal, Breast 5Urinary Bladder Neoplasms 4Sarcoma 4HER2-positive Early Breast Cancer 4HER2 Positive Breast Cancer 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3

Interventions

pertuzumab 2Paclitaxel 2Neoadjuvant Therapy 2Docetaxel 2Carboplatin 2pyrotinib 1pegfilgrastim 1Trastuzumab 1Mastectomy, Modified Radical 1Letrozole 1Hydralazine 1Doxorubicin 1Cyclophosphamide 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Breast Cancer × Trastuzumab × Breast × Clear all
NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
7 enrolled 10 charts
Breast

Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡